drugset / Trial / NCT00695292
Irinotecan, Carboplatin, and Sunitinib in First Line Extensive-Stage Small Cell Lung Cancer
NaSingle-groupOpen-labelTreatment
Summary
This proposed Phase II trial will investigate the combination of irinotecan and carboplatin followed by sunitinib in the first-line treatment of patients with extensive-stage SCLC.
Timeline
- Start
- 2008-06
- Primary completion
- 2011-06
- Completion
- 2012-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carboplatin | Small molecule | — | — |
| Subject | Irinotecan | Small molecule | 60 mg/m2 | Intravenous |
| Subject | Sunitinib | Small molecule | 25 mg | Oral |